ArticleJournal of gastrointestinal oncology2026
The impact of adjuvant chemotherapy on overall survival and cancer-specific survival in patients with extrahepatic cholangiocarcinoma across different age groups: a population-based study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extrahepatic cholangiocarcinoma (ECC) has a high postoperative recurrence rate, and the value of adjuvant chemotherapy (AC) by age remains unclear. This study investigated the influence of AC on long-term survival in patients with ECC, with analysis stratified by age. Methods: Patient data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for individuals diagnosed with ECC from 2010 to 2020. Kaplan-Meier (KM) analysis evaluated the association between AC and long-term survival across age strata. Subsequently, univariate and multivariate Cox regression analyses were performed to analyze the overall survival (OS) and cancer-specific survival (CSS) of ECC patients across different age groups. Furthermore, propensity score matching (PSM) was used to reduce the potential selection bias. Lastly, sensitivity analysis was conducted to assess the robustness of the results. Results: This study included 2,189 patients with ECC, who were divided into four groups according to age: 18-55, 56-65, 66-75 and 76-85 years old. Before PSM adjustment, no statistically significant association was observed between AC and long-term survival in the 18-55 and 56-65 years age groups. In contrast, significant differences in long-term survival were observed in patients aged 66-75 years. For those aged 76-85 years, only OS showed a significant difference. Following adjustment, the absence of significant differences persisted in the two younger age groups. Statistically significant differences in long-term survival, however, were maintained in both the 66-75 and 76-85 years age groups. Multivariate Cox regression analysis demonstrated that patients in the 18-55 and 56-65 years age groups did not benefit from AC. In the 66-75 years age group, AC acted as an independent protective factor. In the 76-85 years age group, AC was an independent protective factor for OS but provided no benefit for CSS. Conclusions: AC conferred age-heterogeneous survival benefits in patients with ECC, wherein the population aged 66-75 years derived the maximum benefit. In contrast, patients aged 18-65 years failed to obtain a statistically significant benefit from AC, while those aged over 75 years exhibited outcome-specific clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.